Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 16/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160648 | 1.00 | ESRRA (0.47) | ESRRAKMT2AMEN1NPC1USP2 | |
| SCHEMBL2201781 | 0.95 | ESRRA (0.48) | ESRRAKMT2AMEN1NPC1USP2 | |
| SCHEMBL13741508 | 0.92 | ESRRA (0.49) | ESRRAKMT2AMEN1NPC1USP2 | |
| SCHEMBL2198899 | 0.90 | ESRRA (0.50) | ESRRAKMT2AMEN1NPC1USP2 | |
| SCHEMBL4165691 | 0.90 | ESRRA (0.50) | ESRRAKMT2AMEN1NPC1USP2 | |
| SCHEMBL4152564 | 0.89 | ESRRA (0.54) | ESRRAKMT2AMEN1NPC1USP2 | |
| SCHEMBL2197524 | 0.89 | ESRRA (0.54) | ESRRAKMT2AMEN1NPC1USP2 | |
| SCHEMBL4155731 | 0.88 | ESRRA (0.51) | ESRRAKMT2AMEN1NPC1USP2 | |
| SCHEMBL2200704 | 0.88 | ESRRA (0.51) | ESRRAKMT2AMEN1NPC1USP2 | |
| SCHEMBL2202068 | 0.87 | ESRRA (0.47) | ESRRAKMT2AMEN1NPC1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977489-B2 | Benzylthiazolone inhibitors of estrogen-related receptors (ERR) | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | claimed |
| US-20090197870-A1 | Pharmaceutical Compositions | EXELIXIS, INC. (US) | 2009-08-06 | — | — | US | claimed |
| EP-1805154-A2 | PHARMACEUTICAL COMPOSITIONS | Exelixis, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006047269-A2 | PHARMACEUTICAL COMPOSITIONS | EXELIXIS, INC. (US) | 2006-05-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197870-A1 | Pharmaceutical Compositions | ESRRA, ESRRB, ESR2 | ESRRA 1/4885KMT2A 1309/4885MEN1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.